5,810 Shares in Jazz Pharmaceuticals PLC $JAZZ Bought by Point Nemo Capital LLC

Key Points

• Point Nemo Capital opened a position in Jazz Pharmaceuticals, buying 5,810 shares worth approximately $1.345 million in the third quarter.
• Jazz reported quarterly revenue of $1.24 billion, up 10.4% year over year and above analyst expectations; its EPS loss of $3.88 was also narrower than forecast. Coverage noted the company raised its 2026 revenue outlook to about $4.78 billion–$4.85 billion.
• Analyst sentiment is broadly positive: the stock has a “Moderate Buy” consensus rating and an average price target of $293.45.

Point Nemo Capital LLC purchased a new position in shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ - Free Report) in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The firm purchased 5,810 shares of the specialty pharmaceutical company's stock, valued at approximately $1,345,000.

A number of other hedge funds also recently modified their holdings of the stock. Bank of New York Mellon Corp grew its holdings in Jazz Pharmaceuticals by 44.5% during the first quarter. Bank of New York Mellon Corp now owns 1,679,371 shares of the specialty pharmaceutical company's stock valued at $317,485,000 after purchasing an additional 517,514 shares during the period. Bank of America Corp DE raised its stake in shares of Jazz Pharmaceuticals by 10.9% in the first quarter. Bank of America Corp DE now owns 1,014,800 shares of the specialty pharmaceutical company's stock valued at $191,848,000 after buying an additional 99,656 shares during the period. Systematic Financial Management LP grew its stake in shares of Jazz Pharmaceuticals by 2.6% during the 1st quarter. Systematic Financial Management LP now owns 407,114 shares of the specialty pharmaceutical company's stock worth $76,965,000 after acquiring an additional 10,237 shares during the period. Quantinno Capital Management LP increased its holdings in Jazz Pharmaceuticals by 9.7% in the 1st quarter. Quantinno Capital Management LP now owns 191,286 shares of the specialty pharmaceutical company's stock worth $36,163,000 after acquiring an additional 16,928 shares during the last quarter. Finally, Tri Locum Partners LP purchased a new stake in Jazz Pharmaceuticals in the 1st quarter worth about $29,995,000. Institutional investors own 89.14% of the company's stock.

Jazz Pharmaceuticals Stock Performance

NASDAQ JAZZ opened at $234.76 on Friday. The company's 50 day simple moving average is $229.39 and its two-hundred day simple moving average is $217.74. The company has a debt-to-equity ratio of 1.09, a current ratio of 1.82 and a quick ratio of 1.58. Jazz Pharmaceuticals PLC has a 1 year low of $128.80 and a 1 year high of $266.38. The stock has a market capitalization of $15.07 billion, a PE ratio of 79.85, a P/E/G ratio of 0.44 and a beta of 0.38.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last released its quarterly earnings results on Monday, November 2nd. The specialty pharmaceutical company reported ($3.88) EPS for the quarter, beating analysts' consensus estimates of ($4.03) by $0.15. The firm had revenue of $1.24 billion during the quarter, compared to analyst estimates of $1.21 billion. Jazz Pharmaceuticals had a net margin of 4.37% and a return on equity of 16.88%. The business's revenue for the quarter was up 10.4% on a year-over-year basis. During the same period in the previous year, the business earned $8.13 EPS. Analysts predict that Jazz Pharmaceuticals PLC will post 11.08 earnings per share for the current fiscal year.

Trending Headlines about Jazz Pharmaceuticals

Here are the key news stories impacting Jazz Pharmaceuticals this week:

• Positive Sentiment: Jazz beat quarterly estimates, reporting $1.24 billion in revenue versus roughly $1.21 billion expected, with revenue up 10.4% year over year. Coverage also reported that the company raised its 2026 revenue outlook to approximately $4.78 billion–$4.85 billion, helping reinforce the growth outlook. Q3 results and outlook
• Positive Sentiment: RBC, Barclays, Morgan Stanley and JPMorgan issued favorable commentary or raised price targets after the results. The analyst optimism adds support to the stock’s post-earnings momentum. Barclays price-target update
• Neutral Sentiment: CEO Renée Galá sold 1,000 shares under a pre-arranged Rule 10b5-1 plan and retained 140,394 shares. Director Bruce Cozadd also sold 6,000 shares under a pre-arranged plan, while CAO Patricia Carr sold 1,413 shares and retained 6,512. These sales may draw investor attention, but planned transactions are not necessarily a signal about near-term business prospects. Insider transaction coverage

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on JAZZ shares. TD Cowen boosted their price objective on Jazz Pharmaceuticals from $275.00 to $300.00 and gave the company a "buy" rating in a research note on Tuesday, August 4th. Morgan Stanley increased their target price on shares of Jazz Pharmaceuticals from $314.00 to $319.00 and gave the stock an "overweight" rating in a research report on Tuesday, November 3rd. Piper Sandler lifted their target price on shares of Jazz Pharmaceuticals from $301.00 to $310.00 and gave the stock an "overweight" rating in a research note on Tuesday, August 4th. The Goldman Sachs Group began coverage on shares of Jazz Pharmaceuticals in a research report on Thursday, September 24th. They issued a "buy" rating and a $337.00 price target on the stock. Finally, Needham & Company LLC boosted their price target on shares of Jazz Pharmaceuticals from $292.00 to $310.00 and gave the company a "buy" rating in a research report on Wednesday, August 26th. One investment analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and two have given a Hold rating to the company. According to data from MarketBeat.com, Jazz Pharmaceuticals presently has an average rating of "Moderate Buy" and an average target price of $293.45.

Insider Buying and Selling at Jazz Pharmaceuticals

In related news, EVP Robert Iannone sold 76,921 shares of the business's stock in a transaction dated Thursday, August 27th. The stock was sold at an average price of $249.70, for a total transaction of $19,207,173.70. Following the completion of the transaction, the executive vice president directly owned 65,686 shares in the company, valued at $16,401,794.20. The trade was a 53.94% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Renée Galá sold 2,000 shares of the company's stock in a transaction dated Tuesday, September 8th. The stock was sold at an average price of $243.03, for a total value of $486,060.00. Following the completion of the transaction, the chief executive officer owned 143,394 shares in the company, valued at $34,849,043.82. This represents a 1.38% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 102,534 shares of company stock valued at $25,185,243 over the last 90 days. Insiders own 4.10% of the company's stock.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing medicines for serious diseases, particularly in neuroscience and oncology. Founded in 2003, the company is headquartered in Dublin, Ireland, and serves patients in the United States and international markets.

Its products include treatments for sleep disorders and seizure conditions, such as Xywav, Xyrem, Sunosi and Epidiolex. Jazz also offers medicines used in cancer care, including Zepzelca, Vyxeos and Rylaze, as well as Defitelio for a serious complication following stem cell transplantation.

Jazz expanded its portfolio through acquisitions, including the 2021 acquisition of GW Pharmaceuticals, which added Epidiolex and other cannabinoid-based medicines.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.